- Home
- SPFI vs RIGL Comparison
SPFI vs RIGL Comparison
Compare SPFI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | RIGL |
|---|---|---|
| Founded | 1941 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 628.4M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SPFI | RIGL |
|---|---|---|
| Price | $41.93 | $29.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $44.00 | $43.20 |
| AVG Volume (30 Days) | 61.5K | ★ 266.4K |
| Earning Date | 04-27-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 2.55 | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $22.65 | $66.81 |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $16.39 | ★ $6.20 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $30.01 | $15.50 |
| 52 Week High | $44.00 | $52.24 |
Technical Indicators
Market Signals| Indicator | SPFI | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 28.55 |
| Support Level | $41.33 | $27.23 |
| Resistance Level | $43.75 | $31.26 |
| Average True Range (ATR) | 1.12 | 1.68 |
| MACD | -0.13 | -0.21 |
| Stochastic Oscillator | 39.98 | 15.63 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.